Ilumya

(Tildrakizumab-asmn)

Ilumya

Drug updated on 11/16/2023

Dosage FormInjectable (subcutaneous; 100 mg/mL)
Drug ClassInterleukin-23 antagonists
Ongoing and Completed StudiesClinicalTrials.gov

Indication

  • Indicated for the treatment of adults with moderate-to-severe plaque psoriasis who are candidates for systemic therapy or phototherapy.

Product Monograph / Prescribing Information

Document TitleYearSource
Ilumya (tildrakizumab-asmn) Prescribing Information2020Sun Pharmaceuticals

Systematic Reviews / Meta-Analyses

Document TitleYearSource
Efficacy and safety of nail psoriasis targeted therapies: a systematic review.2023American Journal of Clinical Dermatology
Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis. 2023Cochrane Database of Systematic Reviews
Efficacy and safety of IL-23 inhibitors in the treatment of psoriatic arthritis: a meta-analysis based on randomized controlled trials. 2023Immunologic research
Adverse Effects of Anti-Interleukin-23 Agents Employed in Patients with Psoriasis: A Systematic Review. 2022Dermatology
Comparative efficacy and safety of biologics in moderate to severe plaque psoriasis: a multiple-treatments meta-analysis.2021Journal of the German Society of Dermatology
Comparative efficacy and relative ranking of biologics and oral therapies for moderate-to-severe plaque psoriasis: a network meta-analysis. 2021Dermatology and Therapy
Comparative safety and benefit-risk profile of biologics and oral treatment for moderate-to-severe plaque psoriasis: a network meta-analysis of clinical trial data.2021Journal of the American Academy of Dermatology
Therapeutic update of biologics and small molecules for scalp psoriasis: a systematic review. 2021Dermatologic Therapy
A systematic review with network meta-analysis of the available biologic therapies for psoriatic disease domains. 2021Frontiers in Medicine
Clinical review report: tildrakizumab (Ilumya). 2021CADTH
A systematic literature review and bucher indirect comparison: tildrakizumab versus guselkumab.2020Journal of Health Economics and Outcomes Research
Systematic review on rapidity of onset of action for interleukin-17 and interleukin-23 inhibitors for psoriasis.2020Journal of the European Academy of Dermatology and Venereology
Comparative efficacy and safety of biologics in moderate to severe plaque psoriasis: a multiple‐treatments meta‐analysis.2020Journal of the German Society of Dermatology
Systemic pharmacological treatments for chronic plaque psoriasis: a network meta‐analysis.2020Cochrane Database of Systematic Reviews
Tildrakizumab: An Evidence-Based Review of Its Use in the Treatment of Moderate-to-Severe Chronic Plaque Psoriasis. 2020Therapeutics and Clinical Risk Management
Tildrakizumab for treating moderate to severe plaque psoriasis.2019NICE
Short-term efficacy and safety of IL-17, IL-12/23, and IL-23 inhibitors brodalumab, secukinumab, ixekizumab, ustekinumab, guselkumab, tildrakizumab, and risankizumab for the treatment of moderate to severe plaque psoriasis: A systematic review and network meta-analysis of randomized controlled trials.2019Journal of Immunology Research
Targeted immunomodulators for the treatment of moderate-to-severe plaque psoriasis: effectiveness and value. 2019ICER
A systematic review and meta-analysis of the efficacy and safety of the interleukin (IL)-12/23 and IL-17 inhibitors ustekinumab, secukinumab, ixekizumab, brodalumab, guselkumab and tildrakizumab for the treatment of moderate to severe plaque psoriasis.2018The Journal of Dermatological Treatment
Public assessment report: Ilumetri.2018EMA

Clinical Practice Guidelines